Rodriguez L A, Prados M, Silver P, Levin V A
Department of Neurosurgery, University of California-San Francisco.
Cancer. 1989 Dec 15;64(12):2420-3. doi: 10.1002/1097-0142(19891215)64:12<2420::aid-cncr2820641204>3.0.co;2-b.
Ninety-nine patients with primary recurrent malignant tumors of the central nervous system were treated with procarbazine as a single agent. Procarbazine was not given as a specified protocol, but for patients who were ineligible or refused other protocols. All patients had been treated previously with radiotherapy and 96 patients had also received previous chemotherapy. Twenty-five patients were treated at the first progression of their tumor, 47 were treated at the second progression, and 27 were treated at the third progression of their tumor. For the aggregate, the response plus stabilization rate was 27% for glioblastoma multiforme with median time to tumor progression of 30 weeks, and 28% for other anaplastic gliomas with a median time to tumor progression of 49 weeks. With respect to the percent of patients who responded or stabilized to treatment, these results are inferior to those reported previously for patients treated with procarbazine at recurrence. With respect to duration of response and stabilization, the data are comparable.
99例原发性中枢神经系统复发性恶性肿瘤患者接受了丙卡巴肼单药治疗。丙卡巴肼并非按照特定方案给药，而是用于不符合其他方案条件或拒绝其他方案的患者。所有患者此前均接受过放疗，96例患者还接受过化疗。25例患者在肿瘤首次进展时接受治疗，47例在第二次进展时接受治疗，27例在第三次进展时接受治疗。总体而言，多形性胶质母细胞瘤的缓解加稳定率为27%，肿瘤进展的中位时间为30周；其他间变性胶质瘤的缓解加稳定率为28%，肿瘤进展的中位时间为49周。就对治疗有反应或病情稳定的患者百分比而言，这些结果低于先前报道的复发性患者接受丙卡巴肼治疗的结果。就反应和病情稳定的持续时间而言，数据具有可比性。
